[A21-172] Diroximel fumarate (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Last updated 01.04.2022
Project no.:
A21-172
Commission:
Commission awarded on 03.01.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Head and nerves
Adults with relapsing remitting multiple sclerosis who have not yet received disease-modifying therapy, or adults with non-highly active disease pretreated with disease-modifying therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.